Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether terlipressin is safe and effective in the treatment of patients with hepatorenal syndrome (HRS) type 1 when compared to placebo.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Mallinckrodt
NCT06525623 · Cirrhosis, Liver, Acute Kidney Injury, and more
NCT06256432 · Hepatorenal Syndrome, Liver Cirrhosis, and more
NCT02434445 · Hepatorenal Syndrome
NCT02097784 · Cirrhosis, Hepatorenal Syndrome, and more
NCT04898010 · Acute Kidney Injury, Hepatorenal Syndrome
Mayo Clinic Hospital
Phoenix, Arizona
University of Arizona College of Medicine
Tucson, Arizona
UCLA School of Medicine
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions